Adagene (ADR) (ADAG)
Develops antibody cancer immunotherapies and licenses tumor-activated masking technology.
Something off on this page? Send us feedback.
Develops antibody-based cancer immunotherapies using the Dynamic Precision Library, with muzastotug as its lead program. It also licenses SAFEbody masking technology and depends on clinical development and collaboration activities.
Builds antibody-based cancer immunotherapies through its Dynamic Precision Library, which supports the NEObody, SAFEbody, and POWERbody technologies. Computational biology supports the discovery and development of these antibody immunotherapies.
Muzastotug, also known as ADG126, is its lead masked anti-CTLA-4 candidate and is being studied with anti-PD-1 therapy. ADG116 is another clinical-stage anti-CTLA-4 antibody; additional earlier programs use NEObody and SAFEbody.
The business also licenses SAFEbody masking technology to drug developers. Progress depends on clinical development of its candidates and on research, development, and commercialization activities under collaborations with Sanofi and Exelixis.
Company facts
Target rangeAs of Sep 22, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Sep 14, 2026 | H.C. Wainwright | Reiterate | Rating: —Target: $5 | Target: $7 |
| Sep 10, 2026 | Chardan Capital | Target | Target: — | Target: $9 |
| Jul 14, 2026 | Guggenheim | Reiterate | Rating: —Target: — | Target: $10 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $127.9M · Total debt $6.1M · Total assets $133.6M · Shareholders' equity $106.0M
- Revenue
- $1.6M
- Operating income
- −$16.6M
- Net income
- −$16.4M
No dividends on record.
| Institutions | 51.16% | 19.26M ADS | |
|---|---|---|---|
| 36 holders · as of Jun 30, 2026 | |||
| Insiders | 0.01% | 2.0K ADS | |
| 1 holder · as of Aug 18, 2026 | |||
| Other | 48.83% | 18.39M ADS | |
| remainder | |||
37.65M ADS as of Aug 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
The share count is from the company's Dec 2024 annual report; nothing newer is on file here.
Some positions are filed in underlying shares, not receipts; the ratio is unknown, so no percentage.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Jupiter Topco LLCInstitution | 17.71% | 6.67M ADS | as of Jun 30, 2026 |
Deerfield Management Company, L.P. (Series C)Institution | 7.08% | 2.67M ADS | as of Jun 30, 2026 |
Siren, L.L.C.Institution | 7.08% | 2.67M ADS | as of Jun 30, 2026 |
Ameriprise Financial IncInstitution | 4.56% | 1.72M ADS | as of Jun 30, 2026 |
SC China Holding LtdInstitution | 3.57% | 1.34M ADS | as of Jun 30, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Sep 16, 2026 | Peter Luo | director, officer: Chief Executive Officer | +20,290 | $3.15 |
| Aug 14, 2026 | Cuong V. Do | director | +2,000 | $3.75 |
| Aug 4, 2026 | Peter Luo | director, officer: Chief Executive Officer | +22,966 | $3.65 |
| Aug 5, 2026 | Peter Luo | director, officer: Chief Executive Officer | +279 | $3.65 |
- Agenus
Fc-enhanced anti-CTLA-4 program in MSS colorectal cancer
- Bristol-Myers Squibb
Approved anti-CTLA-4 therapy Yervoy across cancer indications
- AstraZeneca (ADR)
Approved anti-CTLA-4 therapy Imjudo in combination regimens
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Adagene (ADR) | $3.01 | −6.92% | $121.6M | — | — | 13.1 | — |
| Agenus | $8.50 | −2.30% | $362.3M | 3.3 | — | 2.7 | +34.3% |
| Bristol-Myers Squibb | $61.76 | −0.79% | $127.16B | 13.7 | 9.7 | 2.6 | +5.7% |
| AstraZeneca (ADR) | $164.56 | −2.26% | $261.12B | 25.3 | 15.5 | 4.3 | +6.4% |
| Median | 13.7 | 12.6 | 2.7 | +6.4% |